The class of nitroimidazoles includes compounds that are important antiparasitic agents, which have a broad spectrum of action and high biological activity. For instance, metronidazole (1), secnidazole (2), tinidazole (3), ornidazole (4), dimetridazole (5), carnidazole (6) and panidazole (7) ([Fig. 1](#f01){ref-type="fig"}) are some examples of drugs currently used to treat infections of anaerobic *Bacteroides* sp. and protozoans, such as *Trichomonas*sp., *Entamoeba*sp., *Giardia*sp. and *Histomonas*sp. ([@B60], [@B58], [@B10], [@B35], [@B52]). In addition, nitroimidazoles have other interesting properties, including antitubercular and antifungal activities, in the control of fertility ([@B8], [@B16]), as radiosensitisers ([@B40], [@B28], [@B31] and against the recombinant reverse transcriptase of human immunodeficiency virus (HIV)-1 ([@B46], [@B2]).

Fig. 1: structures of the nitroimidazole drugs (1-7).

The 2-nitroimidazole benznidazole (BZ) (8) ([Fig. 2](#f02){ref-type="fig"}) and nifurtimox (NFX) are the only available drugs for the treatment of Chagas disease. However, these nitro derivatives exhibit poor activity in the late chronic phase, with severe collateral effects and limited efficacy against different parasitic isolates, justifying the urgent need to identify alternatives to treat chagasic patients (Soeiro & de Castro 2011, [@B51]. This disease is caused by *Trypanosoma cruzi* and affects approximately eight million individuals in Latin America. Furthermore, it is emerging in nonendemic areas, associated with the immigration of infected individuals ([@B25], [@B45], [@B24]). Megazol (9) ([Fig. 2](#f02){ref-type="fig"}) is a nitroimidazole-thiadiazole with high in vitro and in vivo activity against *Trypanosoma cruzi*, including against strains resistant to 8 ([@B23], de Castro & de Meirelles 1986, [@B30], [@B44]) and *Trypanosoma brucei*, the causative agent of human African trypanosomiasis (HAT) ([@B19], [@B20], [@B6]. The mode of action of 9 is associated with the interference with the parasite's oxygen metabolism, as well as acting as a trypanothione scavenger ([@B53], [@B33]. Despite its notable trypanocidal activity, 9 was not approved for clinical use due to reports of in vitro mutagenic and genotoxic effects associated with the reduction of the nitro group ([@B21], [@B42], [@B37]), but the nature of the mutagenic metabolite was not yet characterised.

Fig. 2: chemical structures of the nitroimidazoles: benznidazole (8), megazol (9) and a metronidazole analog (10).

Several nitroimidazoles possess good oral therapeutic activity against protozoal parasites; however, concerns over toxicity, mutagenicity and genotoxicity have made drug development problematic. These adverse properties appear to be related to DNA damage by the products of the bio-reduction of the nitro group. In fact, positive Ames tests were observed for 1 and 8 using *Salmonella typhimurium* (Rosenkranz Jr et al. 1976). Despite these results, nitroimidazoles are employed for the clinical treatment of bacterial and protozoal infections and 1 was included the World Health Organization list of Essential Medicines, a list of the arsenal of key antimicrobial drugs ([@B57]).

Studies of the mutagenicity have shown that there are differences in the ability of mammalian cells, bacteria and protozoa to reduce nitroimidazoles ([@B36]). However, to date, there are no conclusive results from analogous studies of mutagenicity performed in vitro in animals or in humans ([@B41]). [@B54] described the influences of different substituent groups in the nitroimidazole ring on the redox system, while [@B56] group demonstrated that the mutagenic action of 1 is affected by different substituents at position 1 of the imidazole nucleus. For example, compound 10 ([Fig. 2](#f02){ref-type="fig"}), which is a position structural analogue of 1, maintained its biological activity without toxic effects. Although some hypotheses exist, active research in this area has yet to produce a comprehensive mechanism to explain the toxic and therapeutic activities of these compounds. Thus, further studies to elucidate the relationship between the biological activity, genotoxicity and mutagenicity of nitroimidazoles are needed.

Our group has investigated new nitroimidazoles as trypanocidal agents and their mutagenic/genotoxic activities. We have observed that these activities do not only depend on the nitro group ([@B7], [@B14], [@B11], [@B12], [@B15], [@B13], [@B34]). Encouraged by this observation, in the present work we evaluated the genotoxic, mutagenic and antitrypanocidal activities of nine nitroimidazoles (11-19) ([Fig. 3](#f03){ref-type="fig"}). The following key structural aspects of the nitroimidazoles were examined: the importance of the position of the nitro group in the imidazole nucleus (C-4 or C-5), the incorporation of an oxidisable group at N-1 of the nitroimidazole ring, as an anion receptor group and the importance of the methyl group at C-2. This study may serve as a guide to the search for new lead compounds for the chemotherapy of human trypanosomiasis and may also identify safer compounds that may serve as the basis for investigation into the mutagenic activity of nitroimidazoles.

Fig. 3: chemical structures of the studied nitroimidazoles 11-19.

Although the focus of this work is studying the genotoxic and mutagenic effects of different nitroimidazole moieties, the synthesised compounds (11-19) were also assayed against *T. cruzi*, even though they do not possess the structural requirements required for trypanocidal activity, i.e., two aromatic and/or heteroaromatic rings.

MATERIALS AND METHODS
=====================

*Chemistry* - 4 or 5-nitroimidazoles with different substituents at the 2 position (11-19) were synthesised following the method described by [@B47]. Stock solutions of the compounds were prepared in dimethyl sulfoxide (DMSO) and in all subsequent assays control sets with the highest required solvent concentrations (5%) were included.

*In vitro trypanocidal assay* - Bloodstream trypomastigotes *of T. cruzi* were obtained from mice intraperitoneally inoculated with the Y strain of *T. cruzi* and were resuspended in Dulbecco's modified Eagle's medium plus 10% foetal calf serum at a concentration of 10^7^ parasites/mL. This suspension (100 μL) was added to an equal volume of 11 to 19 and incubated for 24 h at 37ºC under a 5% CO~2~ atmosphere. Cell counts were then performed using a Neubauer chamber and the concentration that produced lysis of 50% of the parasites (IC~50~) was determined. Untreated and BZ-treated parasites were used as controls ([@B13]). The experiments were conducted in accordance with the guidelines established by the Oswaldo Cruz Foundation Committee of Ethics for the Use of Animals (LW 16-13).

*In vitro treatment and cytotoxicity assay in whole blood* - Heparinised human blood was obtained by venipuncture immediately before the assays. Whole blood was treated for 2 h at 37ºC with different concentrations of 9 (380-4,000 µM) and of 11 to 19 (148-6,400 µM). The cell viability was determined using the fluorescein diacetate (FDA)/ethidium bromide (EtBr)-assay, in which viable cells are labelled in green, while dead ones display orange-stained nuclei ([@B26]). Whole blood (50 µL) was mixed with an equal volume of a freshly prepared staining solution consisting of 30 µg/mL FDA plus 8 µg/mL EtBr in phosphate-buffered saline (PBS). Samples (50 µL) were spread on a microscope slide, covered with a coverslip and observed using a fluorescence microscope. Two hundred cells were analysed for each treatment. This toxicity test was performed to determine the range of drug concentrations in the subsequent approaches: concentrations that led to more than 30% loss of viability were excluded ([@B3], [@B27]).

*In vitro alkaline single cell gel electrophoresis (SCGE) or the comet assay* - At the end of a 2 h-treatment, DNA damage in the whole blood was evaluated in duplicate using an alkaline comet assay ([@B49]). Methyl methane-sulfonate (MMS) (160 µM) (Aldrich, USA) was used as a positive control. Aliquots of 5 µL of whole blood were mixed with 120 µL of 0.5% low melting-point agarose (LMPA) (Sigma-Aldrich, USA) in PBS at 37ºC and were applied to microscope slides previously covered with 1.5% normal melting-point agarose (Sigma-Aldrich). Then, the slides were covered with coverslips and after LMPA solidification (3 min/4-5ºC), the coverslips were removed and the slides were immersed in cold lysing solution (2.5 M NaCl, 100 mM Na~2~EDTA, 10 mM Tris, 1% N-lauroylsarcosine sodium salt, 1% Triton X-100, 10% DMSO, pH 10) for at least 1 h at 4-5ºC, protected from light. Afterwards, the slides were placed in a horizontal gel electrophoresis unit (Bio-Rad) filled with a freshly prepared alkaline buffer at a pH \> 13 (300 mM NaOH, 1 mM EDTA). The times for the alkali treatment and the electrophoresis of the DNA (0.86 V/cm and 300 mA) were 20 min each in an ice bath. The slides were neutralised by washing three times (5 min) in Tris buffer (0.4 M Tris, pH 7.5), dried, fixed in absolute ethanol (99.8%) for approximately 10 min and left at room temperature overnight. Then, each slide was covered with 30 µL of EtBr (20 µg/mL) and a coverslip and analysed using a fluorescence microscope at 400X magnification.

Fifty random cells per slide (200 cells per treatment) were visually analysed in a blinded manner according to tail size into four classes of damage: 0 (undamaged, i.e., no visible tail), 1 (slightly damaged), 2 (moderately damaged) and 3 (maximally damaged, i.e., the head of comet was very small and most of the DNA was in the tail) ([@B29]). DNA damage was expressed as arbitrary units (AU) as percentage of cells into each of the four classes according to the formula AU = (0 x M0) + (1 x M1) + (2 x M2) + (3 x M3).

The codes M0, M1, M2 and M3 correspond to the number of cells within damage classes 0, 1, 2 and 3, respectively. Thus, the total DNA damage score \[total arbitrary units (TAU)\] for 200 comets range from zero (undamaged) to 600 (maximally damaged). The experiments were performed in triplicate and the statistical significance (p \< 0.05) between the treated and control groups was evaluated using Student's one-tailed *t*test ([@B29], [@B38])

*Salmonella/Microsome mutagenicity test* - Four samples with nitro group at positions 4 (16 and 17) and 5 (13 and 18) and different substituent groups at position N-1 were selected for this analysis ([Fig. 3](#f03){ref-type="fig"}). The *Salmonella*/Microsome mutagenicity test evaluates mutations in the DNA of genetically modified *Salmonella enterica* serovar *Typhimurium* strains that lack the ability to synthesise histidine (*His* ^-^). The strains TA97, TA98, TA100, TA102 and TA1535 were utilised following the guidelines for the testing of chemicals ([@B32]). At least five strains of bacteria were used, including four strains of *S. enterica* serovar *typhimurium* (TA1535; TA1537 or TA97a or TA97; TA98 and TA100).

A volume of 100 µL of the nitroimidazole (25-2,500 µM), 500 µL of PBS and 100 µL of the bacterial suspension (2 x 10^9^ cells/mL) were combined in a test tube. Next, 2 mL of top agar (7 g/L agar; 5 g/L NaCl; 0.0105 g/L L-histidine; 0.0122 g/L biotin; pH 7.4, 45ºC) was added and the mixture was poured into a Petri dish containing minimal agar {15 g/L agar, Vogel-Bonner E medium 10X \[10 g/L MgSO~4~.7H~2~O; 100 g/L C~6~H~8~O~7~.H~2~O; 500 g/L K~2~HPO~4~; 175 g/L Na(NH~4~)HPO~4~.4H~2~O\]} with 20 g/L glucose. The plates were incubated at 37ºC for 72 h and the *His* ^*+*^ revertant colonies were counted. The positive controls included 1.0 µg/plate 4-nitroquinoline-N-oxide (4-NQO) for TA97 and TA98, 0.5 µg/plate sodium azide for TA100 and TA1535 and 0.5 µg/plate mitomycin C for TA102. All of the chemicals were obtained from Sigma Co (USA). DMSO was used as the negative control. The sample was considered positive for mutagenicity when the following conditions were observed: the number of revertant colonies in the assay was at least twice the number of spontaneous revertants \[mutagenicity index (MI) ≥ 2\], a significant response to the analysis of variance (p ≤ 0.05) was observed and a reproducible, positive dose-response curve (p ≤ 0.01) was obtained. The MI was calculated by dividing the number of *His*^*+*^ colonies induced in the sample by the number of *His*^*+*^ colonies in the negative control. All the experiments were performed in triplicate and were repeated twice. Statistical significance was evaluated using analysis of variance, including a one-way ANOVA and Tukey's honestly significant difference HSD *post hoc* analysis (p ≤ 0.01). The mutagenic potency slope was obtained using the Bernstein model ([@B5]).

*Survival experiments* - Quantitative evaluations were performed to determine the cytotoxic effects of the nitroimidazoles by the Ames test. Ten microlitres of each treated bacterial suspension (10^8^ cells/mL) was diluted in a saline solution (NaCl, 9 g/L-0.9%). Then, 100 µL of the solution was placed on a Petri dish containing nutrient agar \[0.8% bacto nutrient broth (Difco), 0.5% NaCl and 1.5% agar\] and incubated at 37ºC for 24 h. The colonies were counted and the survival percentage was determined with respect to the negative control. All the experiments were performed in triplicate and were repeated twice ([@B1]).

RESULTS
=======

The present study focused on the use of SCGE to evaluate DNA damage induced by the nitroimidazoles 11-19 with the objective of mapping genotoxic activity, as displayed in [Table I](#t1){ref-type="table"}. The treatment of blood cells with 9 over the range of 380-4,000 µM for 2 h at 37°C did not reduce the cell viability. However, a highly significant (p \< 0.01) genotoxic effect was observed at concentrations higher than of 1,562 µM. The positive control, MMS, was highly active at 160 µM (p \< 0.0001), causing a clear genotoxic effect with a TAU value of 454.3 ± 9.2. In the range of 148-6,400 µM, the nitroimidazoles 11, 12, 16 and 18 did not alter cellular viability and caused no DNA damage compared to the control group (p \> 0.05). On the other hand, at the same concentrations, 13, 15 and 19 caused moderate alterations to the DNA, whereas 14, 17 and 9 caused strong alterations of the DNA structure.

TABLE IAnti-*Trypanosoma cruzi* and genotoxic in vitro activities of nitroimidazoles 11-19CompoundIC~50~/24 h (µM)Genotoxic99.9 ± 0.83111,690.9 ± 371.80121,147.3 ± 111.60131,749.7 ± 184.61141,170.7 ± 100.53151,585.8 ± 218.31161,132.4 ± 86.30171,049.4 ± 63.7318\> 2,000019902.6 ± 83.41[^1]

The nitroimidazoles were also assayed against *T. cruzi*. Compounds 11-17 and 19 exhibited an IC~50~ in the range of 902-1,749 µM, whereas for 18, this parameter was \> 2000 µM. Under the same experimental conditions, the values for 8 and 9 were 9.7 ± 2.4 and 9.9 ± 0.8 µM, respectively ([Table I](#t1){ref-type="table"}). As expected, the compounds were not active trypanocides because they do not possess the structural requirements required for trypanocidal activity, i.e., two aromatic and/or heteroaromatic rings.

[Fig. 4](#f04){ref-type="fig"} illustrates the mutagenicity and cytotoxicity induced by nitroimidazoles 13, 16, 17 and 18 using *S. typhimurium* strains TA97, TA98, TA100, TA102 and TA1535. At concentrations between 25-2,500 µM, these compounds did not induce frameshift mutations in TA97. However, compounds 17 and 18 were capable of inducing frameshift mutations in TA98, whereas 18 also induced transversions and transitions in TA102 and base pair substitutions in TA1535. Furthermore, all of the nitroimidazoles were capable of inducing dose-dependent base pair substitutions for at least two tested doses in TA100, the most mutagen-responsive strain ([Fig. 5](#f05){ref-type="fig"}). In addition, cytotoxic activity was present only in the higher concentration (2,500 µM) for at least one sample and strain. Using the Bernstein correlation, the number of revertant colonies per µg (rev/µg) was deduced. In addition, higher mutagenic potency correlated with an increased risk of being a mutagen.

Fig. 4: *Salmonella*/Microsome assay of the nitroimidazoles 13, 16, 17 and 18. rev/mM: revertant colonies per nM.

Fig. 5: genotoxic (comet assay) and mutagenic (*Salmonella*/Microsome assay) response of the nitroimidazoles 13, 16, 17 and 18.

DISCUSSION
==========

Although nitroimidazoles have been clinically used for chemotherapy against several parasites, the mechanisms underlying their genotoxic and biological activities are not fully understood. On the basis of the high activity of 9 against trypanosomatids ([@B23], [@B19], [@B17]) together with the success of NFX-eflornithine for the treatment of HAT ([@B61]), the Drugs for Neglected Diseases initiative triggered a systematic review of more than 700 nitroheterocycles (mostly nitroimidazoles) ([@B50]). In this context, fexinidazole (5-nitroimidazole), first described in 1978 by [@B59], emerged as a potential candidate. The development of this compound was previously abandoned largely due to the prejudice against nitroaromatic compounds ([@B39]). More recently, analysis of pharmacological and toxicological profiles suggested that fexinidazole is a promising candidate for both HAT ([@B50]) and Chagas disease ([@B4]). These facts and our previous results prompted us to re-evaluate the role of the nitro group in the toxic effects of nitroimidazoles. The presence of a nitro group in a compound can result in several toxicity issues, including genotoxicity and mutagenicity ([@B55]). However, at the same time, this functional group is necessary for the desired biological activity. Consequently, nitrocompounds are not included in screening libraries due to this unwanted functionality ([@B9]) and are not synthesised in medicinal chemistry programs \[reviewed in [@B39]\].

This work investigated the importance of different functional groups of C-4 or C-5 nitroimidazoles having oxidisable groups bonded at N-1 on the biological and mutagenic activities of the compounds.

The results of the genotoxicity assays are described in [Table I](#t1){ref-type="table"}. Nitroimidazoles 11 and 12, which contain a NO~2~ group at C-4 and a CH~3~ group at C-2, were not genotoxic compared to 13, 14 and 15, which possess a NO~2~ group at C-5 and exhibited moderate to high genotoxicity. Nitroimidazole 13 had moderate mutagenic effects. We also observed a comparable result between 11 (2-CH~3~ and 4-NO~2~), which was not genotoxic and its analogue 4 (2-CH~3~ and 5-NO~2~), which is known to be a mutagenic agent ([@B22]). However, when the nitroimidazole had no CH~3~group at C-2, the position of the NO~2~ group had no influence on genotoxic activity. This is the case for 16 (4-NO~2~) and 18 (5-NO~2~), which exhibited behaviours similar to that of 11 and 12 (no genotoxicity). When comparing pairs of similar compounds, for instance, 16 (4-NO~2~ and N-CH~2~OAcCH~2~Cl) with 17 (4-NO~2~ and N-CH~2~OAcCH~2~F) and 14 (2-CH~3~; 5-NO~2~; N-CH~2~OHCH~2~F) with 15 (2-CH~3~; 5-NO~2~; N-CH~2~OHCH~2~OH), we observed that the presence of fluorine induced genotoxicity. The fluorinated compounds 14 and 17 showed higher genotoxicity regardless of the presence of CH~3~ at C-2 or NO~2~ at C-4 or C-5. However, when comparing compounds 11 (2-CH~3~; 4-NO~2~; N-CH~2~OHCH~2~Cl) and 12 (2-CH~3~; 4-NO~2~; N-CH~2~OHCH~2~F), the fluorine atom had no influence on genotoxicity.

Four compounds were selected for the Ames assays \[nitro group at positions 4 (16 and 17) and 5 (13 and 18) and different substituent groups at position N-1\] with the aim of clarifying whether the increase in mutagenicity of nitroimidazoles was dependent only on the position of the nitro group or was related to the presence of more or less reactive halogens.

The results of the cytotoxicity and mutagenicity analyses are described in [Fig. 4](#f04){ref-type="fig"} and [Table II](#t2){ref-type="table"}. The four *S. typhimurium* strains have GC base pairs at the primary reversion site and as a result, it is known that these strains may not detect certain oxidising mutagens, cross-linking agents and hydrazines. Such substances may be detected by *S. typhimurium* TA102, which has an AT base pair at the primary reversion site ([@B38]). The data showed that 17 is a highly potent mutagen (41.7 rev/µg to TA100), whereas 13, 16 and 18 are low-potency mutagens, causing approximately 8-9 rev/µg. The data in [Fig. 5](#f05){ref-type="fig"} further corroborate this finding, on the basis that the number of TAU in the comet assay is high for 17, similar to the number of rev/µg.

TABLE IIGenotoxicity, mutagenicity and mutagenic potency slope of nitroimidazoles 13, 16, 17 and 18CompoundGenotoxicityAmes test (MI \> 2) - MutagenicityMutagenic potency slope (revertants/µg)1,562 µM250 µM1,250 µM2,500 µMTA97TA98TA100TA102TA1535131 (300 TAU)-TA100TA1000.30 ± 0.22NA8.98 ± 0.71NANA160 (10 TAU)-TA100TA100NANA6.60 ± 0.63NANA173 (411 TAU)TA100TA100TA98, TA100NA0.55 ± 0.0841.70 ± 3.712.51 ± 0.44NA180 (32 TAU)-TA100TA98, TA100, TA102, TA15352.13 ± 0.140.69 ± 0.058.18 ± 0.15NA0.51 ± 0.07[^2]

In conclusion, we observed that the type and position of different substituents bonded to the imidazole ring have a significant influence on the toxicological activity. Whereas nitroimidazoles 11 and 12 were not genotoxic, nitroimidazoles 13, 15 and 19 were moderately genotoxic and mutagenic. Nitroimidazole 16 was neither genotoxic nor mutagenic and 18 was moderately mutagenic but not genotoxic. These results demonstrate that the nitro group is not solely responsible for the mutagenic or genotoxic activity.

Furthermore, the data suggest that the nitroimidazole may be the moiety most likely to be responsible for the genotoxic and mutagenic effects, but in the analogues tested, this moiety was unable to provide anti-*T. cruzi* activity.
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[^1]: 0: undamaged; 1: slightly damaged; 2: moderately damaged; 3: maximally damaged (see Materials and Methods for more details).

[^2]: MI: mutagenicity inde; NA: not applicable; TAU: total arbitrary units for the positive control, methyl methane-sulfonate value was 454.3 ± 9.2.
